Ftse Mib
36.200,72
0,24%
DAX
21.394,93
-0,11%
S&P 500
6.101,24
-0,29%
NASDAQ
19.954,30
-0,50%
Bitcoin
104.503,12
-0,22%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Oncocyte Corporation (OCX) Oncocyte Corporation (OCX) Notizie

Oncocyte Corporation

OCX
2,03
0,02 (1,00%)
25 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/1/202522:05EDGAR2Form 8-K - Current report
08/1/202514:30GLOBEOncocyte Appoints Dr. Paul Billings as Consulting Chief..
06/1/202522:05GLOBEOncocyte Expands Market Opportunity for VitaGraft™ Kidney
09/12/202422:05GLOBEOncocyte to Participate in “J.P. Morgan Week” and Host..
09/12/202414:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202422:15GLOBEOncocyte Demonstrates Potential for Liquid Biopsy of Brain..
02/12/202422:05GLOBEOncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection..
12/11/202422:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202422:05EDGAR2Form 8-K - Current report
12/11/202422:05GLOBEOncocyte Reports Commercial Launch Progress; On Track to..
06/11/202422:45GLOBEOncocyte To Announce Third Quarter 2024 Financial Results on..
22/10/202422:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/10/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
18/10/202422:55EDGAR2Form S-3/A - Registration statement under Securities Act of..
16/10/202423:16EDGAR2Form S-3 - Registration statement under Securities Act of..
16/10/202422:15GLOBEOncocyte Announces Participation in the LD Micro Main Event..
15/10/202422:22EDGAR2Form 8-K - Current report
15/10/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/10/202414:30GLOBEOncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response..
05/10/202401:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202412:05EDGAR2Form 8-K - Current report
03/10/202400:41GLOBEOncocyte Signs Leading Transplant Centers in US and Germany
03/10/202400:35GLOBEOncocyte Corporation Announces $10.2 Million Private..
25/9/202422:09EDGAR2Form DEF 14A - Other definitive proxy statements
20/8/202415:00GLOBEPRISM MarketView Features Oncocyte CFO Andrea S. James on..
12/8/202422:10GLOBEOncocyte’s VitaGraft™ Kidney Used to Monitor Effect of..
09/8/202412:37EDGAR2Form 8-K - Current report
09/8/202412:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/8/202422:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202422:10EDGAR2Form 8-K - Current report
08/8/202422:05GLOBEOncocyte Announces Successful GraftAssure™ Beta Launch and..
05/8/202422:05GLOBEOncocyte Announces August Investor Conferences Participation
01/8/202422:05GLOBEOncocyte to Announce Second Quarter 2024 Financial Results..
12/7/202422:05EDGAR2Form 8-K - Current report
11/7/202414:00GLOBEMedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in..
24/6/202418:41GLOBEOncocyte Bolsters Executive Team with Key CFO Appointment:..
17/6/202422:10EDGAR2Form 8-K - Current report
17/6/202422:05GLOBEOncocyte Appoints Andrea James as Chief Financial Officer
04/6/202423:02EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
03/6/202420:13GLOBEBreakthrough in Kidney Transplant Monitoring: PRISM..
31/5/202422:05EDGAR2Form 8-K - Current report
30/5/202422:47GLOBEFavorable Oncocyte VitaGraft Kidney Study Results Published..
23/5/202422:05EDGAR2Form 8-K - Current report
23/5/202417:26EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/5/202423:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202423:11EDGAR2Form S-3/A - Registration statement under Securities Act of..
15/5/202422:05GLOBEOncocyte Reports First Quarter 2024 Financial Results
13/5/202414:00GLOBEOncocyte to Announce First Quarter 2024 Financial Results
10/5/202423:31EDGAR2Form S-3 - Registration statement under Securities Act of..
Apertura: 2,00 Min: 2,00 Max: 2,08
Chiusura: 2,01

La tua Cronologia

NASDAQ
OCX
Oncocyte
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network